Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn's disease

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 11000-11011

  Bao, Chun Hui ^a   Zhao, Ji Meng ^a   Liu, Hui Rong ^a   Lu, Yuan ^a   Zhu, Yi Fang ^a   Shi, Yin ^b   Weng, Zhi Jun ^b   Feng, Hui ^c   Guan, Xin ^a   Li, Jing ^a   Chen, Wei Feng ^d   Wu, Lu Yi ^a   Jin, Xiao Ming ^e   Dou, Chuan Zi ^b   Wu, Huan Gan ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Shanghai Institute of Acupuncture Moxibustion and Meridian   (China)

^c Guanghua Hospital of Integrative Medicine   (China)

^d FUDAN UNIVERSITY   (China)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acupuncture; Crohn's disease; Moxibustion; Randomized controlled trial; Traditional chinese medicine

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; BIOLOGICAL MARKER;

ACUPUNCTURE; ADULT; ARTICLE; BURN; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; ENDOSCOPY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOXIBUSTION; OUTCOME ASSESSMENT; PAIN; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAFETY; THERAPY EFFECT; TREATMENT DURATION; WHEAT BRAN; BLOOD; CHINA; MIDDLE AGED; REMISSION; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ACUPUNCTURE THERAPY; ADULT; BIOLOGICAL MARKERS; CHINA; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOXIBUSTION; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84909641296     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.11000     Document Type: Article

References (41)

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380: 1590-1605 [PMID: 22914295 DOI: 10.1016/S0140-6736(12)60026-9]
2. Zheng JJ, Zhu XS, Huangfu Z, Shi XH, Guo ZR. Prevalence and incidence rates of Crohn's disease in mainland China: a meta-analysis of 55 years of research. J Dig Dis 2010; 11: 161-166 [PMID: 20579219 DOI: 10.1111/j.1751-2980.2010.00431.x]
3. Gray WN, Denson LA, Baldassano RN, Hommel KA. Disease activity, behavioral dysfunction, and health-related quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1581-1586 [PMID: 21674715 DOI: 10.1002/ibd.21520]
4. Iglesias M, Vázquez I, Barreiro-de Acosta M, Figueiras A, Nieto L, Piñeiro M, Gómez R, Lorenzo A, Domínguez Muñoz JE. Health related quality of life in patients with Cohn's disease in remission. Rev Esp Enferm Dig 2010; 102: 624-630 [PMID: 21142382]
5. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther 2006; 23: 377-385 [PMID: 16422997 DOI: 10.1111/j.1365-2036.2006.02753.x]
6. Casellas F, Vivancos JL, Sampedro M, Malagelada JR. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life. Am J Gastroenterol 2005; 100: 2737-2742 [PMID: 16393228 DOI: 10.1111/j.1572-0241.2005.00360.x]
7. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014; 63: 72-79 [PMID: 23135759 DOI: 10.1136/gutjnl-2012-303376]
8. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-339 [PMID: 17631151 DOI: 10.1053/j.gastro.2007.05.006]
9. Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion 2004; 69: 131-139 [PMID: 15114043 DOI: 10.1159/000078151]
10. Shi Y, Bao CH, Wu HG, Chen WF, Qin XD, Zhang R, Wu LY. Effects of herbs-partitioned moxibustion on the expressions of intestinal mucosa TNF-α, TNFR1, TNFR2 and apoptosis of intestinal epithelial cells in Crohn's disease patients. Shanghai Zhongyiyao Zazhi 2011; 45: 46-50
11. Joos S, Wildau N, Kohnen R, Szecsenyi J, Schuppan D, Willich SN, Hahn EG, Brinkhaus B. Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 2006; 41: 1056-1063 [PMID: 16938719 DOI: 10.1080/00365520600580688]
12. Zhou EH, Liu HR, Wu HG, Shi Z, Zhang W, Zhu Y, Shi DR, Zhou S. Down-regulation of protein and mRNA expression of IL-8 and ICAM-1 in colon tissue of ulcerative colitis patients by partition-herb moxibustion. Dig Dis Sci 2009; 54: 2198-2206 [PMID: 19083096 DOI: 10.1007/s10620-008-0620-4]
13. Park JW, Lee BH, Lee H. Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis. BMC Complement Altern Med 2013; 13: 247 [PMID: 24088418 DOI: 10.1186/1472-6882-13-247]
14. Anastasi JK, McMahon DJ, Kim GH. Symptom management for irritable bowel syndrome: a pilot randomized controlled trial of acupuncture/moxibustion. Gastroenterol Nurs 2009; 32: 243-255 [PMID: 19696601 DOI: 10.1097/SGA.0b013e3181b2c920]
15. Park YC, Kang W, Choi SM, Son CG. Evaluation of manual acupuncture at classical and nondefined points for treatment of functional dyspepsia: a randomized-controlled trial. J Altern Complement Med 2009; 15: 879-884 [PMID: 19678778 DOI: 10.1089/acm.2008.0369]
16. Ma TT, Yu SY, Li Y, Liang FR, Tian XP, Zheng H, Yan J, Sun GJ, Chang XR, Zhao L, Wu X, Zeng F. Randomised clinical trial: an assessment of acupuncture on specific meridian or specific acupoint vs. sham acupuncture for treating functional dyspepsia. Aliment Pharmacol Ther 2012; 35: 552-561 [PMID: 22243034 DOI: 10.1111/j.1365-2036.2011.04979.x]
17. Schneider A, Streitberger K, Joos S. Acupuncture treatment in gastrointestinal diseases: a systematic review. World J Gastroenterol 2007; 13: 3417-3424 [PMID: 17659687]
18. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-846 [PMID: 467941]
19. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-296 [PMID: 8299896]
20. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810 [PMID: 2644154]
21. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-989 [PMID: 2668130 DOI: 10.1136/gut.30.7.983]
22. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267 [PMID: 9453485 DOI: 10.1016/S0016-5085(98)70476-7]
23. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-530 [PMID: 11832465 DOI: 10.1053/gast.2002.3107]
24. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665 [PMID: 15472532 DOI: 10.1097/00054725-200409000-00026]
25. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006; 55: 1561-1567 [PMID: 16648154 DOI: 10.1136/gut.2005.084301]
26. Bao CH, Wu LY, Wu HG, Shi Y, Liu HR, Zhang R, Yu LQ, Wang JH. Moxibustion inhibits apoptosis and tumor necrosis factor-alpha/tumor necrosis factor receptor 1 in the colonic epithelium of Crohn's disease model rats. Dig Dis Sci 2012; 57: 2286-2295 [PMID: 22531889 DOI: 10.1007/s10620-012-2161-0]
27. Bao CH, Wu LY, Shi Y, Wu HG, Liu HR, Zhang R, Yu LQ, Wang JH. Moxibustion down-regulates colonic epithelial cell apoptosis and repairs tight junctions in rats with Crohn's disease. World J Gastroenterol 2011; 17: 4960-4970 [PMID: 22174545 DOI: 10.3748/wjg.v17.i45.4960]
28. Shi Z, Ma XP, Wu HG, Qin XD, Qian QL, Zhang W. Effect of acupuncture-moxibustion on TNF-α, sTNFR-I and sTNFR-II of rats with Crohn's disease. J Acupunct Tuina Sci 2009; 7: 29-32 [DOI: 10.1007/s11726-009-0029-4]
29. Wu HG, Liu HR, Tan LY, Gong YJ, Shi Y, Zhao TP, Yi Y, Yang Y. Electroacupuncture and moxibustion promote neutrophil apoptosis and improve ulcerative colitis in rats. Dig Dis Sci 2007; 52: 379-384 [PMID: 17211698 DOI: 10.1007/s10620-006-9561-y]
30. Wang XM, Lu Y, Wu LY, Yu SG, Zhao BX, Hu HY, Wu HG, Bao CH, Liu HR, Wang JH, Yao Y, Hua XG, Guo HY, Shen LR. Moxibustion inhibits interleukin-12 and tumor necrosis factor alpha and modulates intestinal flora in rat with ulcerative colitis. World J Gastroenterol 2012; 18: 6819-6828 [PMID: 23239920 DOI: 10.3748/wjg.v18.i46.6819]
31. Wang X, Zhou S, Yao W, Wan H, Wu H, Wu L, Liu H, Hua X, Shi P. Effects of Moxibustion Stimulation on the Intensity of Infrared Radiation of Tianshu (ST25) Acupoints in Rats with Ulcerative Colitis. Evid Based Complement Alternat Med 2012; 2012: 704584 [PMID: 23258997]
32. Zhou EH, Liu HR, Wu HG, Shi Y, Wang XM, Yao LQ, Zhong YS, Yang Y. Herb-partition moxibustion relieves chronic visceral hyperalgesia and 5-HT concentration in colon mucosa of rats. Neurol Res 2009; 31: 734-737 [PMID: 19108755 DOI: 10.1179/174313209X382313]
33. Liu HR, Yang Y, Wu HG. Clinical study on acupuncture in treating diarrhea-predominant irritable bowel syndrome. J Acupunct Tuina Sci 2008; 6: 360-362 [DOI: 10.1007/s11726-008-0360-1]
34. Vincent C, Lewith G. Placebo controls for acupuncture studies. J R Soc Med 1995; 88: 199-202 [PMID: 7745565]
35. Avis NE, Legault C, Coeytaux RR, Pian-Smith M, Shifren JL, Chen W, Valaskatgis P. A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes. Menopause 2008; 15: 1070-1078 [PMID: 18528313 DOI: 10.1097/gme.0b013e31816d5b03]
36. Yeung WF, Chung KF, Tso KC, Zhang SP, Zhang ZJ, Ho LM. Electroacupuncture for residual insomnia associated with major depressive disorder: a randomized controlled trial. Sleep 2011; 34: 807-815 [PMID: 21629370]
37. Haake M, Müller HH, Schade-Brittinger C, Basler HD, Schäfer H, Maier C, Endres HG, Trampisch HJ, Molsberger A. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med 2007; 167: 1892-1898 [PMID: 17893311 DOI: 10.1001/Archinte.167.17.1892]
38. Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007; 128: 264-271 [PMID: 17257756 DOI: 10.1016/j.pain.2006.12.006]
39. Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011; 56: 2088-2097 [PMID: 21380937 DOI: 10.1007/s10620-011-1653-7]
40. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
41. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667 [PMID: 18295023 DOI: 10.1016/S0140-6736(08)60304-9]